TICKERNERD
Menu
ATOSATOSHealthcare · Biotechnology

ATOS Stock Forecast: Atossa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$2.37
−0.42% on the day

The 2 Wall Street analysts covering Atossa Therapeutics, Inc. hold a median 12-month price target of $22 — +828.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 27 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$23.8M
Ticker Nerd rank
26/ 100
Median analyst target
$22
Analysts covering
2
Revenue$0.0
Operating income−$8.7M
Net income−$8.5M
Free cash flow−$9.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.3%
1M
+20.9%
YTD
−73.2%
1Y
−83.2%
From 52W high
−83.2%
From 52W low
+35.4%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ATOS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Atossa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
26/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Revisions
70
Accruals
47
Volatility
46
Issuance
41
Quality
35
Value
19
Growth
16
Momentum
1

Size (86): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ATOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ATOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26ATOSHigh $25Median $22Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $10Median $22High $25

The green dot is the last close — the median target sits +828.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Oct 2026Ascendiant CapitalMaintainsBuy$24 → $25
7 July 2026Rodman & RenshawInitiatesBuy—
7 July 2026Rodman & RenshawInitiatesBuy$12
10 Apr 2026Ascendiant CapitalMaintainsBuy—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
6 June 2025Ascendiant CapitalMaintainsBuy—
5 June 2025Craig-HallumInitiatesBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025HC Wainwright & Co.ReiteratesBuy—
13 Dec 2024HC Wainwright & Co.ReiteratesBuy—
12 Dec 2024HC Wainwright & Co.ReiteratesBuy—
9 Dec 2024Ascendiant CapitalMaintainsBuy—
13 Nov 2024HC Wainwright & Co.MaintainsBuy—
5 Nov 2024HC Wainwright & Co.ReiteratesBuy—
31 Oct 2024HC Wainwright & Co.ReiteratesBuy—
11 Sept 2024Ascendiant CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ATOS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ATOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Atossa Therapeutics, Inc. returned −83.2% against +13.6% for the S&P 500, dividends included.

ATOS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ATOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ATOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Atossa Therapeutics, Inc. (ATOS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−89.2%

Higher than 15% of US stocks

Return on assets
−50.7%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Atossa Therapeutics, Inc. (ATOS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Atossa Therapeutics, Inc. has a market value of $23.8M and an enterprise value of −$2.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$35.8M.

  • Shares outstanding: 10.0M.

  • Trailing P/E: −0.6×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Atossa Therapeutics, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

ATOS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ATOSAtossa Therapeutics, Inc.$23.8M26
CELUCelularity, Inc.$25.6M33
CNTXContext Therapeutics, Inc.$21.6M25
NXTCNextCure, Inc.$26.2M72
BSEMBioStem Technologies, Inc.$26.4M59
CVMCEL-SCI Corp.$27.4M39
PLRZPolyrizon Ltd.$20.4M15

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Atossa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ATOS news & analysis

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today

PRNewsWire · 19 Oct 2026neutral

Atossa Therapeutics said each common share outstanding at the close of business on October 19, 2026, will receive one stapled contingent value right (CVR). Shares and their attached CVRs will transfer together under the CVR Agreement.

Why it matters — ATOS shareholders and observers may want to note the CVR attachment and the terms governing how the rights transfer with shares.

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

PRNewsWire · 9 Oct 2026positive

Atossa Therapeutics entered a definitive agreement implementing its stapled contingent value rights plan. The board declared one CVR for each common share outstanding on October 19, 2026, or issued thereafter; holders are entitled to 25% of net proceeds from monetizing the company's first qualifying priority review voucher, subject to a $50 million aggregate cap.

Why it matters — The agreement sets out how eligible shareholders could participate in proceeds if Atossa monetizes a qualifying priority review voucher.

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

PRNewsWire · 29 Sept 2026neutral

Atossa Therapeutics announced that its Board of Directors approved a plan to issue one contingent value right (CVR) for each share of common stock, entitling shareholders to 25% of net proceeds from the monetization of the company's first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap.

Why it matters — This plan outlines a mechanism through which existing and future ATOS shareholders could receive a portion of any proceeds from a potential priority review voucher monetization.

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

PRNewsWire · 24 Sept 2026neutral

Atossa Therapeutics announced that its CEO, Dr. Steven Quay, will participate in a panel at the ARDD 2026 conference held at Harvard University, focused on clinical trials and regulatory pathways for diseases of aging. The event will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways.

Why it matters — ATOS watchers would care because it highlights the company's engagement with academic and regulatory discussions relevant to its clinical-stage pipeline in aging-related diseases.

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

PRNewsWire · 7 Aug 2026neutral

Atossa Therapeutics announced its financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate developments. The company described its execution during the quarter as strong.

Why it matters — The financial results and corporate update offer ATOS watchers insight into the company's recent operational progress and financial health as a clinical-stage biopharmaceutical company.

FAQ

Frequently asked questions about ATOS stock

What is the ATOS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Atossa Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ATOS stock a buy right now?

Of the 2 analysts covering Atossa Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atossa Therapeutics, Inc. 26 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ATOS?

As at 27 Oct 2026, Atossa Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will ATOS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +828.3% from the last close, and Ticker Nerd's factor model ranks Atossa Therapeutics, Inc. 26 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ATOS stock forecast for 2030?

No analyst covering Atossa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.

How has ATOS stock performed over the past year?

Atossa Therapeutics, Inc. returned -83.2% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Atossa Therapeutics, Inc. do?

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions.

What is the latest news on ATOS?

The most recent item we track (PRNewsWire, 19 Oct 2026): "Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today". Atossa Therapeutics said each common share outstanding at the close of business on October 19, 2026, will receive one stapled contingent value right (CVR). Shares and their attached CVRs will transfer together under the CVR Agreement.

Company

About Atossa Therapeutics, Inc.

Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs. Its current pipeline includes investigational medicines and therapeutic programs designed to address breast cancer prevention and treatment, as well as selected rare diseases where estrogen-related biology may be relevant. Atossa Therapeutics also advances diagnostic capabilities connected to breast health, supporting a broader approach to disease management. Based in Seattle, Washington, the company operates within the biotechnology sector and plays a role in translating research into potential treatment options for women’s health and cancer care.

CEO Dr. Steven C. Quay FCAP, M.D., Ph.D. · 16 employees · United States · https://www.atossatherapeutics.com